Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja maintains a Buy rating on Neurocrine Biosciences (NBIX) and raises the price target from $164 to $170.

May 02, 2024 | 6:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja maintains a Buy rating on Neurocrine Biosciences and raises the price target from $164 to $170.
The increase in price target by Guggenheim reflects a positive outlook on Neurocrine Biosciences, likely due to strong company fundamentals or positive market data. This endorsement from a reputable analyst could lead to increased investor confidence and a potential short-term uptick in NBIX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100